Notably, the UBE2O crosslinking inhibitor arsenic trioxide (ATO) reduced PD-L1 expression and enhanced the efficacy of radioimmunotherapy in preclinical lung cancer models while exhibiting acceptable short-term tolerability. Our findings indicate that targeting the UBE2O/CDKL1 axis may represent a highly promising strategy for increasing lung cancer sensitization to radioimmunotherapy.

We identified polyprenoic acid (PA, peretinoin) as the first ligand capable of directly binding HNF4A...Importantly, hepatocyte-specific Hnf4a knockdown or lipid-nanoparticle-mediated Hnf4a siRNA abrogated the protective effects of PA. These findings establish HNF4A as a pharmacologically controllable tumor suppressor and highlight PA-like compounds as promising agents for preventing liver carcinogenesis.

P1/2, N=16, Recruiting, Misty Shields | Not yet recruiting --> Recruiting | Initiation date: May 2026 --> Aug 2026

Histopathological analysis showed that the combination group had less cell proliferation (as evidenced by reduced Ki-67 expression) and greater tumor necrosis. This study reveals the synergistic effects of Oncomed and ATO, suggesting a potential combinatorial strategy to address the limitations of current cancer treatments and improve patient outcomes.

P2/3, N=450, Enrolling by invitation, First Affiliated Hospital of Zhejiang University

P2/3, N=267, Enrolling by invitation, First Affiliated Hospital of Zhejiang University

P2, N=9, Active, not recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting --> Active, not recruiting | Trial completion date: Dec 2025 --> Jun 2027 | Trial primary completion date: Mar 2025 --> Dec 2026

Acute promyelocytic leukemia (APL) is a highly curable form of acute myeloid leukemia (AML) when treated early with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO)...The ATRA-ATO regimen showed substantial remission rates, but early deaths remain a concern. Increased survival rates in resource-constrained environments require improved early detection, referral, and supportive care.

P1, N=20, Recruiting, University Health Network, Toronto | Not yet recruiting --> Recruiting

Suspicion for DS should be heightened in patients with acute promyelocytic leukemia (M3 AML) who recently started induction chemotherapy, including all-trans retinoic acid or arsenic trioxide, and in those with non-M3 AML receiving differentiation agents (i.e., isocitrate dehydrogenase inhibitors, menin inhibitors, FMS-like tyrosine kinase 3 inhibitors)... DS represents a diagnostic challenge in the ED due to its nonspecific presentation and mimicry of infection. A high index of suspicion, combined with targeted imaging, laboratory evaluation, and early corticosteroid therapy, can improve outcomes.

c-Myc activation is a key driver of VEN resistance in t(8;21) AML. HHT acts as a mechanistically complementary agent, restoring VEN sensitivity. These results provide a preclinical rationale for clinical evaluation of VEN-HHT combination therapy in genetically defined AML subsets.

P2, N=46, Not yet recruiting, Dongguan People's Hospital